1. Home
  2. NRXP vs IOTR Comparison

NRXP vs IOTR Comparison

Compare NRXP & IOTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXP
  • IOTR
  • Stock Information
  • Founded
  • NRXP 2015
  • IOTR 2019
  • Country
  • NRXP United States
  • IOTR Singapore
  • Employees
  • NRXP N/A
  • IOTR N/A
  • Industry
  • NRXP Biotechnology: Pharmaceutical Preparations
  • IOTR
  • Sector
  • NRXP Health Care
  • IOTR
  • Exchange
  • NRXP Nasdaq
  • IOTR NYSE
  • Market Cap
  • NRXP 32.6M
  • IOTR 29.5M
  • IPO Year
  • NRXP N/A
  • IOTR 2025
  • Fundamental
  • Price
  • NRXP $3.27
  • IOTR $0.41
  • Analyst Decision
  • NRXP Strong Buy
  • IOTR
  • Analyst Count
  • NRXP 4
  • IOTR 0
  • Target Price
  • NRXP $28.50
  • IOTR N/A
  • AVG Volume (30 Days)
  • NRXP 298.7K
  • IOTR 451.3K
  • Earning Date
  • NRXP 08-13-2025
  • IOTR 01-01-0001
  • Dividend Yield
  • NRXP N/A
  • IOTR N/A
  • EPS Growth
  • NRXP N/A
  • IOTR N/A
  • EPS
  • NRXP N/A
  • IOTR N/A
  • Revenue
  • NRXP N/A
  • IOTR $9,578,336.00
  • Revenue This Year
  • NRXP N/A
  • IOTR N/A
  • Revenue Next Year
  • NRXP N/A
  • IOTR N/A
  • P/E Ratio
  • NRXP N/A
  • IOTR N/A
  • Revenue Growth
  • NRXP N/A
  • IOTR 13.93
  • 52 Week Low
  • NRXP $1.10
  • IOTR $0.31
  • 52 Week High
  • NRXP $6.01
  • IOTR $5.98
  • Technical
  • Relative Strength Index (RSI)
  • NRXP 66.15
  • IOTR N/A
  • Support Level
  • NRXP $2.90
  • IOTR N/A
  • Resistance Level
  • NRXP $3.61
  • IOTR N/A
  • Average True Range (ATR)
  • NRXP 0.28
  • IOTR 0.00
  • MACD
  • NRXP -0.03
  • IOTR 0.00
  • Stochastic Oscillator
  • NRXP 64.59
  • IOTR 0.00

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

Share on Social Networks: